Meeting
2019 Genitourinary Cancers Symposium
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
Authors
Arlene O. Siefker-Radtke
The University of Texas MD Anderson Cancer Center, Houston, TX
Arlene O. Siefker-Radtke , Mayer N. Fishman , Arjun Vasant Balar , Giovanni Grignani , Adi Diab , Jianjun Gao , Mary Ann Tagliaferri , Alison L. Hannah , Erin E. Karski , Jonathan Zalevsky , Ute Hoch , Ahsan NAQI Rizwan , Mehmet Asim Bilen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02983045
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 388)
DOI
10.1200/JCO.2019.37.7_suppl.388
Abstract #
388
Poster Bd #
G1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
First Author: Petros Grivas
Poster
2020 Genitourinary Cancers Symposium
PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).
First Author: Robert A. Huddart
Poster
2020 Genitourinary Cancers Symposium
FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)—Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement.
First Author: Matt D. Galsky
Poster
2019 ASCO Annual Meeting
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
First Author: Michael E. Hurwitz